YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Dr. Curtis Schreiber led CMH's participation in the study.
SBJ file
Dr. Curtis Schreiber led CMH's participation in the study.

CMH assists Eli Lilly in drug trial, FDA next

Posted online

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is preparing to submit an Alzheimer’s drug to the U.S. Food and Drug Administration for approval after assistance from Citizens Memorial Hospital in Bolivar.

The CMH Missouri Memory Center participated in a nationwide clinical trial with positive results in Alzheimer’s disease treatment, according to a news release. Eli Lilly's donanemab drug would be used for early-symptomatic Alzheimer’s patients.

“Alzheimer’s disease is the most common form of dementia, and it starts subtly but progresses relentlessly,” said Dr. Curtis Schreiber, medical director of the Missouri Memory Center and CMH Research Department, in the release. “While medications are currently available for treating the symptoms of Alzheimer’s, researchers continue to explore scientific approaches to actually slowing the progression of the symptoms.

"Options for slowing this unforgiving disease may be on the horizon.”

The Phase III study that CMH participated in found 47% of patients who used donanemab showed no decline based on a key measure of disease severity during the first year; had a 40% less decline in their ability to perform daily living activities at 18 months; and had a 39% lower risk of progressing to the next stage of the disease.

"We are extremely pleased that donanemab yielded positive clinical results with compelling statistical significance for people with Alzheimer's disease in this trial," said Dr. Daniel Skovronsky, Lilly's chief scientific and medical officer, in a separate news release.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
From the Ground Up: Republic Intermediate School

The Republic School District is on track to open its Intermediate School for fifth- and sixth-grade students for the 2025-26 academic year.

Most Read
Update cookies preferences